CURE9h
First Patient Dosed in Trial of [212Pb]VMT01 for Metastatic Melanoma
The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with ...
Did Scientists Just Cure Baldness? UCLA’s New Molecule Could Revolutionize Hair Growth
UCLA genetic scientists are reawakening hibernating follicles. A UCLA-discovered molecule, PP405, may finally offer real hope ...
How melanoma and other tumors succeed in hiding and resisting immunotherapy
Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of ...
Immatics N.V.: Trading Below Cash, But Not Without Reason
Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns ...
Aura Biosciences Stock (AURA) Continues to Slide Despite Promising Clinical Progress
Aura Biosciences (AURA) has reported its Q4 and full-year 2024 financial results, prompting an ongoing decline in shares ...
TMCnet6d
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
As of December 31, 2024, Aura had cash and cash equivalents and marketable securities totaling $151.1 million. The Company believes its current cash and cash equivalents and marketable securities are ...